VTGN

VistaGen Therapeutics Inc. is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California, committed to pioneering innovative therapeutics for anxiety, depression, and other central nervous system disorders. The company is advancing its proprietary drug candidates, particularly AV-101, which targets substantial unmet needs in mental health treatment. With a robust focus on neuropharmacology and an emerging pipeline of promising therapies, VistaGen is strategically positioned to address the evolving demands of CNS therapeutics, making it an attractive opportunity for institutional investors seeking to capitalize on cutting-edge advancements in this critical healthcare sector.